 Home > Active Ingredient News > Antitumor Therapy > CAR-T cell therapy Idecabagene Vicleucel for relapsed refractive multiple myeloma: submitted to BLA.

CAR-T cell therapy Idecabagene Vicleucel for relapsed refractive multiple myeloma: submitted to BLA.

 Last Update: 2020-08-04
 Source: Internet
 Author: User

Tags

cell cycle inhibitors

food research

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Multiple myeloma is a form of plasma cell carcinoma.
the cause of multiple myeloma is not yet known and there is no cure.
however, there are many treatments that can be used to treat multiple myeloma.
patients who had been exposed to three major drugs, including IMiD drugs, PI, and anti-CD38 antibodies, had fewer treatment choices and poor prognosis, including shorter reaction times and lower total survival, so new treatments were urgently needed.
Bristol Myers Squibb and Bluebird today announced that they have filed their biolicense (BLA) with the U.S. Food and Drug Administration (FDA).
idecabagene vicleucel (ide-cel, bb2121) is a research-targeted B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of relapsed refractive lysic multiple myeloma.
Critical II KarMMa study evaluated the effectiveness and safety of patients who had been exposed to immunomodulators (IMiD), protease inhibitors (Pi), and recurrent, refractory multiple myeloma with anti-CD38 antibodies.
the results of the study were presented at the American Society of Clinical Oncology (ASCO20) virtual meeting in 2020.
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.